Treatment for male hair loss using dutasteride injections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of two different techniques for administering dutasteride to treat androgenetic alopecia in Brazilian men aged 18 to 65. The study will compare traditional syringe injections with a novel method using a tattoo machine for mesotherapy. A total of 60 participants will be randomized to receive one of the two treatment methods, with a focus on assessing hair growth outcomes. The trial aims to determine which administration technique yields better results in hair restoration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy volunteers male patients.
* Aged 18 to 65 years.
* Patients with male androgenetic alopecia (grades III - V of the Norwood/Hamilton scale)
* Commitment not to initiate any other treatment, topical, systemic or intralesional, that interferes with hair growth during the study period.
* Patient without systemic treatment for AGA (5 reductase inhibitors) for more than 12 months or without topical treatment for more than 6 months before the start of the study.
* Allow the creation of two micro tattoos (maximum size of 1 mm each, resembling a hairy infundibulum) in the area that will be treated, in order to standardize the trichoscopic analysis.
* With the aim of photographic standardization, the patient must agree to have their hair cut in a standardized way in the first and last interventions.
* Patient about to get his partner pregnant.
* Patient must refrain from donating blood during the investigation and up to 6 months after the last intervention,
* Patient must abstain from drinking alcoholic beverages, abstain from using inhaled or injectable drugs, abstain from using illicit drugs within 30 days of entering the study,
* Patients without a psychiatric diagnosis and who behave appropriately during the interview,
* Signs of good hygiene and that have the ability to keep the areas undergoing treatment clean until they heal,
* Patients who understand and speak Portuguese,
* Patients with realistic expectations regarding the final benefits of treatment,
* Needle phobia,
* Independent patient, eliminating the need for tutoring or legal representative,
* Absence of chronic viral diseases, for example HIV, hepatitis B or hepatitis C,
* Absence of other skin diseases, for example lichen planus, psoriasis, Crohn's disease or ulcerative colitis,
* Absence of immunosuppression, for example: lymphoma, transplant therapy, chronic corticosteroid use, Wiskott-Aldrich Syndrome or uncontrolled malignancy,
* Patients/participants with previously known allergies or those detected during the interventions (anesthetics, topical antibiotics or other medications used in the trials),
* Absence of clinically significant cardiovascular disease (e.g. previous myocardial infarction), absence of coagulopathy or use of anticoagulants, absence of neurological disease (e.g. stroke, cerebral ischemia), absence of renal, hepatic or endocrine disease (e.g. example, diabetes).
* Patient/participant with medical conditions not mentioned, which in the investigator's view, prohibit participation in the study.
* Signature of informed consent

Exclusion Criteria:

* Detection during the test of allergy to the medicines used (anesthetics, topical antibiotics or other medicines used in the tests),
* Breach of protocol, inappropriate conduct that compromises participant safety or interferes with the interpretation of study results,
* Any illness or condition, which in the judgment of the investigators, interferes with the participant's ability to complete or terminate the investigation.

Where it's running

• Clinica Dermatologica Arbache
  São José dos Campos, São Paulo, Brazil Recruiting

Study contacts

• Study coordinator: SAMIR ARBACHE, PhD
• Email: samir.arbache@gmail.com
• Phone: 12 981221011

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual treatment with KeraFactor and Revian LED for female pattern hair loss

  This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.

  Recruiting K. Kay Durairaj, MD, FACS, A Medical Corporation · Pasadena, California · NCT07810504

• Two hair supplements for men with androgenic alopecia

  This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.

  Recruiting at 6 sites Activ'inside · Rende, Cosenza and 5 other locations · NCT07806474

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• 2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia

  This trial will test whether a once-daily topical 2‑Deoxy‑D‑ribose hydrogel is as effective and safe as 5% minoxidil for adults aged 18 to 50 with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07502976

• TH07 topical treatment for male pattern hair loss

  This trial will test whether a new daily topical spray called TH07 helps men aged 18–49 with male pattern hair loss grow more hair than standard minoxidil or a placebo over 24 weeks.

  Recruiting Phase 3 Triple Hair Inc · Vancouver, British Columbia · NCT07435012

• Umbilical cord mesenchymal stem cell exosome treatment for male pattern hair loss in young men

  This trial will test whether injections of umbilical cord mesenchymal stem cell exosomes can regrow hair or slow hair loss in men aged 18–35 with androgenic alopecia compared with topical 5% minoxidil.

  Recruiting Phase 1/2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07203599

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.